Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stella PharmaTSE:4888 -0.31%74 Days Payable is 1,106.54 as of Mar. 2026, which is 104% above its 10-year median of 541.10. GuruFocus rates TSE:4888 with a GF Score™ of 74/100 and a GF Value™ of 円337.87 (Fairly Valued). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, Stella Pharma ranks better than 72.9% on this metric.
The historical rank and industry rank for Stella Pharma's Days Payable or its related term are showing as below:
TSE:4888'
s Days Payable Range Over the Past 10 Years
Min: 155.74 Med: 541.1 Max: 1322.4
Current: 342.65
During the past 8 years, Stella Pharma's highest Days Payable was 1322.40. The lowest was 155.74. And the median was 541.10.
TSE:4888's Days Payable is ranked better than 72.9% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs TSE:4888: 342.65
Stella Pharma's Days Payable
increased
from Mar. 2025 (44.51) to Mar. 2026 (1,106.54).
It may suggest that Stella Pharmadelayed paying its suppliers.
Stella Pharma Days Payable Related Terms
Stella Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Stella Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4888 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Stella Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Stella Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Stella Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stella Pharma (TSE:4888) has a Days Payable of 1,106.54 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Stella Pharma and its competitors. This is 104% above median its historical median of 541.10. Over the past decade, Stella Pharma's Days Payable has ranged from 155.74 to 1,322.40. According to the industry distribution chart, Stella Pharma ranks #190 out of 701 companies in the Biotechnology industry, placing it in the top 27.1%.
Is Stella Pharma's Days Payable too high?
Stella Pharma's current Days Payable of 1,106.54 is 104% above median its 10-year median of 541.10. Over the past 10 years, this metric has ranged from a low of 155.74 to a high of 1,322.40. The Biotechnology industry median Days Payable is 112.84. Stella Pharma's value of 1,106.54 is 880.6% above this industry median. Based on the distribution chart, Stella Pharma ranks #190 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stella Pharma has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #190 out of 701 companies for Days Payable. This puts Stella Pharma in the upper half of its industry. The industry median Days Payable is 112.84. Stella Pharma's value of 1,106.54 is 880.6% above this benchmark. Historically, Stella Pharma's own Days Payable has ranged from 155.74 to 1,322.40 over the past decade. While the company's 10-year median is 541.10 vs. the industry median of 112.84, Stella Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stella Pharma's current Days Payable of 1,106.54 is 880.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Stella Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stella Pharma's current Days Payable is 1,106.54, which is 104% above median its own 10-year median of 541.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円337.87, compared to a current price of 円325.00 — trading 3.8% below its estimated fair value. The current Days Payable is 1,106.54, which is 104% above median its 10-year median of 541.10 and 880.6% above the Biotechnology industry median of 112.84. Stella Pharma's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Days Payable is 1,106.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円325.00 is trading 3.8% below its estimated GF Value™ of 円337.87.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
Days Payable: 1,106.54 (104% above median its 10-year median of 541.10)
GF Value™: 円337.87 vs. price of 円325.00 (3.8% below fair value)
Industry Position: 880.6% above the Biotechnology median (#190 of 701)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
74GF Score
Get the complete analysis for TSE:4888
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
